ROCO
4162
Market cap257mUSD
Oct 08, Last price
57.20TWD
1D
2.51%
1Q
-11.32%
Jan 2017
-62.18%
IPO
-74.86%
Name
PharmaEngine Inc
Chart & performance
P/E
21.20
P/S
9.02
EPS
2.70
Div yield, %
10.49%
Shrs. gr., 5y
-0.27%
Rev. gr., 5y
-2.90%
Revenues
911m
-63.88%
Net income
388m
-77.86%
CFO
1.73b
+278.09%
Dividend
Aug 17, 20262 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irinotecan. This topoisomerase 1 inhibitor is designed to treat metastatic pancreatic cancer. The company's pipeline also includes PEP06, currently in Phase I clinical trials for various cancers, and PEP07. PEP07, a Chk1 inhibitor in preclinical development, is being investigated for its ability to induce DNA damage and programmed cell death (apoptosis), leading to "replication catastrophe" in cancer cells. Established in 2002, PharmaEngine, Inc. maintains its corporate headquarters in Taipei, Taiwan.
Key people
Jan-Yau Hsu
Chairman of the Board · since 2022
Hong-Ren Wang
General Manager · since 2021
Chi-Hsing Chang
Deputy General Manager-Corporate Development, Corporate Governance Officer · since 2019
Peggy Tsao
Head of Finance & Accounting · since 2021
Ming-Feng Hou
Director · since 2021
Director · since 2022
Yi-Hui Lin
Director · since 2018
Ming-Shiang Wu
Director · since 2022
Director · since 2018
Independent Director · since 2022
Chien-Huang Lin
Independent Director · since 2021
Pau-Chu Lo
Independent Director · since 2025
Wenda Qiu
Independent Director · since 2025
Chih-Li Wang
Independent Director · since 2019
IPO date
Sep 01, 2011
Employees
Domiciled in
TW
Incorporated in
TW
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||